Search
Now showing items 51-54 of 54
Inflammatory Myofibroblastic Tumour: State of the Art.
(MDPI, 2022-07-27)
An inflammatory myofibroblastic tumor (IMT) is a neoplasm composed of myofibroblastic and fibroblastic spindle cells accompanied by inflammatory cells, including lymphocytes and eosinophils. It is an ultra-rare tumor, the ...
On the road to improved outcomes by capturing leiomyosarcoma patients' views.
(FUTURE MEDICINE LTD, 2022-10-03)
An international collaborative project set up as a 'priority setting partnership' used a questionnaire to capture the views of patients, carers and clinicians about the sarcoma research agenda. Responses from 25 patients ...
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.
(ELSEVIER, 2022-08-01)
BACKGROUND: Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, is approved for the treatment of adult patients with advanced gastrointestinal stromal ...
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
(WILEY, 2021-08-16)
BACKGROUND: Ripretinib 150 mg once daily (QD) is indicated for advanced gastrointestinal stromal tumors (GISTs) as at least fourth-line therapy. In INVICTUS, ripretinib intrapatient dose escalation (IPDE) to 150 mg b.i.d. ...